Works matching IS 2160763X AND DT 2021 AND VI 10 AND IP 8

Results: 13

Napabucasin Drug‐Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 8, p. 824, doi. 10.1002/cpdd.961

By:

Dai, Xiaoshu;
Karol, Michael D.;
Hitron, Matthew;
Hard, Marjie L.;
Goulet, Matthew T.;
McLaughlin, Colleen F.;
Brantley, Scott J.

Publication type:

Article

Bioequivalence for a Fixed‐Dose Combination Formulation of Bazedoxifene and Cholecalciferol Compared With the Corresponding Single Entities Given Together.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 8, p. 850, doi. 10.1002/cpdd.958

By:

Yun, Jae Nam;
Kan, Hye‐Su;
Yeun, Ji‐Sun;
Kim, Jae‐Hoon;
Lee, Minyu;
Kim, Namsick;
Oh, Tae‐Young;
Nam, Seung‐Kwan;
Choi, Yoon Seok;
Kwon, In Sun;
Hoe, Kwang Lae;
Hong, Jang Hee

Publication type:

Article

Bioequivalence of 2 Aripiprazole Orally Disintegrating Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 8, p. 840, doi. 10.1002/cpdd.954

By:

Xiang, Jin;
Xu, Nan;
Wang, Xueyan;
LI, Songfan;
Yu, Qin;
Liang, Maozhi;
Nan, Feng;
Shu, Shiqing;
Yan, Rui;
Zhu, Yuqi;
Liao, Linchuan

Publication type:

Article

Thorough QT/QTc Evaluation of the Cardiac Safety of Enarodustat (JTZ‐951), an Oral Erythropoiesis‐Stimulating Agent, in Healthy Adults.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 8, p. 884, doi. 10.1002/cpdd.933

By:

Pai, Sudhakar M.;
Yamada, Hiroyuki;
Kleiman, Robert B.;
Zhuo, Rui;
Huang, Qingtao;
Koretomo, Ryosuke

Publication type:

Article

Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitor.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 8, p. 950, doi. 10.1002/cpdd.927

By:

Chavan, Ajit;
Burke, Leontia;
Sawant, Rishikesh;
Navarro‐Gonzales, Pamela;
Vargo, Dennis;
Paulson, Susan K.

Publication type:

Article

Differential Effect of a Continental Breakfast on Tacrolimus Formulations With Different Release Characteristics.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 8, p. 899, doi. 10.1002/cpdd.924

By:

Huppertz, Andrea;
Bollmann, Johanna;
Behnisch, Rouven;
Bruckner, Thomas;
Zorn, Markus;
Burhenne, Jürgen;
Haefeli, Walter E.;
Czock, David

Publication type:

Article

A Phase 1 Study of KHK4083: A Single‐Blind, Randomized, Placebo‐Controlled Single‐Ascending‐Dose Study in Healthy Adults and an Open‐Label Multiple‐Dose Study in Patients With Ulcerative Colitis.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 8, p. 870, doi. 10.1002/cpdd.918

By:

Furihata, Kenichi;
Ishiguro, Yoh;
Yoshimura, Naoki;
Ito, Hiroaki;
Katsushima, Shinji;
Kaneko, Etsuji;
Shimabe, Munetake;
Mukai, Mayumi;
Watanabe, Risa;
Morishige, Takuya

Publication type:

Article

A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 8, p. 859, doi. 10.1002/cpdd.914

By:

Leubitz, Andi;
Vanhoutte, Frederic;
Hu, Ming‐yi;
Porter, Kaela;
Gordon, Efrat;
Tencer, Kathleen;
Campbell, Kathleen;
Banks, Kate;
Haverty, Tom

Publication type:

Article

Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D<sub>2</sub>/D<sub>3</sub> Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy Participants

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 8, p. 927, doi. 10.1002/cpdd.906

By:

Whiting, Roger L.;
Darpo, Borje;
Chen, Chunlin;
Fletcher, Margaret;
Combs, Dan;
Xue, Hongqi;
Stoltz, Randall R.

Publication type:

Article

Phase 1 Concentration‐QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRT‐232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 8, p. 918, doi. 10.1002/cpdd.903

By:

Taylor, Adekemi;
Lee, Dana;
Allard, Martine;
Poland, Bill;
Greg Slatter, J.

Publication type:

Article

A Colon‐Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 8, p. 908, doi. 10.1002/cpdd.901

By:

Pinquier, Jean‐Louis;
Varastet, Marina;
Meyers, Dismas;
Sayah‐Jeanne, Sakina;
Féger, Céline;
Gaumétou, Olivia;
Corbel, Tanguy;
de Gunzburg, Jean;
Mentré, France;
Ducher, Annie

Publication type:

Article

Issue Information.

Published in:: Clinical Pharmacology in Drug Development, 2021, v. 10, n. 8, p. 819, doi. 10.1002/cpdd.715
Publication type:: Article

Pharmacokinetics and Safety of PTC596, a Novel Tubulin‐Binding Agent, in Subjects With Advanced Solid Tumors.

Published in:

Clinical Pharmacology in Drug Development, 2021, v. 10, n. 8, p. 940, doi. 10.1002/cpdd.904

By:

Shapiro, Geoffrey I.;
O'Mara, Edward;
Laskin, Oscar L.;
Gao, Lan;
Baird, John D.;
Spiegel, Robert J.;
Kaushik, Diksha;
Weetall, Marla;
Colacino, Joseph;
O'Keefe, Kylie;
Branstrom, Arthur;
Goodwin, Elizabeth;
Infante, Jeffrey;
Bedard, Philippe L.;
Kong, Ronald

Publication type:

Article